[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse SGCA

Summary
SymbolSGCA
Namesarcoglycan, alpha (50kDa dystrophin-associated glycoprotein)
Aliases SCARMD1; LGMD2D; adhalin; DMDA2; 50kD DAG; Sarcoglycan, alpha (50kD dystrophin-associated glycoprotein; adha ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane, sarcolemma Single-pass type I membrane protein Cytoplasm, cytoskeleton
Domain PF05510 Sarcoglycan alpha/epsilon
Function

Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix.

> Gene Ontology
 
Biological Process GO:0003012 muscle system process
GO:0006936 muscle contraction
GO:0007517 muscle organ development
Molecular Function -
Cellular Component GO:0016010 dystrophin-associated glycoprotein complex
GO:0016011 dystroglycan complex
GO:0016012 sarcoglycan complex
GO:0042383 sarcolemma
GO:0045121 membrane raft
GO:0090665 glycoprotein complex
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSGCA
Namesarcoglycan, alpha (50kDa dystrophin-associated glycoprotein)
Aliases SCARMD1; LGMD2D; adhalin; DMDA2; 50kD DAG; Sarcoglycan, alpha (50kD dystrophin-associated glycoprotein; adha ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SGCA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSGCA
Namesarcoglycan, alpha (50kDa dystrophin-associated glycoprotein)
Aliases SCARMD1; LGMD2D; adhalin; DMDA2; 50kD DAG; Sarcoglycan, alpha (50kD dystrophin-associated glycoprotein; adha ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SGCA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSGCA
Namesarcoglycan, alpha (50kDa dystrophin-associated glycoprotein)
Aliases SCARMD1; LGMD2D; adhalin; DMDA2; 50kD DAG; Sarcoglycan, alpha (50kD dystrophin-associated glycoprotein; adha ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SGCA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2220.557
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1520.81
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4980.352
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4590.468
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0520.972
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.970.603
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3490.428
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6270.378
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1380.848
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.3920.161
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8730.518
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.8010.00205
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SGCA in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSGCA
Namesarcoglycan, alpha (50kDa dystrophin-associated glycoprotein)
Aliases SCARMD1; LGMD2D; adhalin; DMDA2; 50kD DAG; Sarcoglycan, alpha (50kD dystrophin-associated glycoprotein; adha ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SGCA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSGCA
Namesarcoglycan, alpha (50kDa dystrophin-associated glycoprotein)
Aliases SCARMD1; LGMD2D; adhalin; DMDA2; 50kD DAG; Sarcoglycan, alpha (50kD dystrophin-associated glycoprotein; adha ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SGCA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SGCA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSGCA
Namesarcoglycan, alpha (50kDa dystrophin-associated glycoprotein)
Aliases SCARMD1; LGMD2D; adhalin; DMDA2; 50kD DAG; Sarcoglycan, alpha (50kD dystrophin-associated glycoprotein; adha ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SGCA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSGCA
Namesarcoglycan, alpha (50kDa dystrophin-associated glycoprotein)
Aliases SCARMD1; LGMD2D; adhalin; DMDA2; 50kD DAG; Sarcoglycan, alpha (50kD dystrophin-associated glycoprotein; adha ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SGCA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSGCA
Namesarcoglycan, alpha (50kDa dystrophin-associated glycoprotein)
Aliases SCARMD1; LGMD2D; adhalin; DMDA2; 50kD DAG; Sarcoglycan, alpha (50kD dystrophin-associated glycoprotein; adha ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SGCA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSGCA
Namesarcoglycan, alpha (50kDa dystrophin-associated glycoprotein)
Aliases SCARMD1; LGMD2D; adhalin; DMDA2; 50kD DAG; Sarcoglycan, alpha (50kD dystrophin-associated glycoprotein; adha ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SGCA collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.